O. I. Gremyakova

O. I. Gremyakova

Auto-generated profile, based on publicly available information

O. I. Gremyakova

Charitable Foundation “Gordey

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 June 2022 in Neuromuscular Diseases
Verified
Journal Article
Open access
PDF file
TGT. A. Gremyakova
T. A. Gremyakova
SASvetlana Artemyeva
Svetlana Artemyeva
NVN. D. Vashakmadze
N. D. Vashakmadze
IVI. P. Vitkovskaya
I. P. Vitkovskaya
VGV. I. Guzeva
V. I. Guzeva
SNS. S. Nikitin
S. S. Nikitin
Duchenne muscular dystrophy (DMD) is a fatal neuromuscular disease due to a mutation in the gene encoding dystrophin synthesis. In patients, muscle damage and atrophy progresses, the ability to move independently decreases as well as respiratory and cardiac functions. At various stages of the disease, different methods of care and treatment of patients with DMD are used. The clinical effect of new methods of DMD target therapy may depend on the stage of development of the disease (ambulatory or non‑ambulatory). To date, there are no unified criteria for assessing the status of a patient in terms ambulatory. In clinical trials and real clinical practice, different approaches are used to assess the patient’s status. However, the conclusion about the functional capabilities is critical for patients with DMD as approaches in management of patients in ambulatory and non‑ambulatory stages differ significantly. This necessitates expert consensus to achieve consistency and avoid any of discrepancies on that issue.The paper reviews the available published data on the concepts of “ambulatory” and “non‑ambulatory” used in clinical trials, real clinical practice, international standards and recommendations. As a conclusion of this analysis, it is proposed in real clinical practice to interpret “ambulation” in DMD patients as ability to walk without the use of assistive devices and without specifying the distance and time, and “non‑ambulation” as condition in which the patient is forced to constantly use a wheelchair both indoors and outdoors.

14 June 2024 in Pediatria. Journal named after G.N. Speransky
Verified
Journal Article
Closed access
ТGТ.а. Gremyakova
Т.а. Gremyakova
MDMoscow “Gordey” Charity Foundation Designated For Providing Systemic Assistance To Patients With Duchenne Muscular Dystrophy
Moscow “Gordey” Charity Foundation Designated For Providing Systemic Assistance To Patients With Duchenne Muscular Dystrophy
ОGО.I. Gremyakova
О.I. Gremyakova
EKElena Kistol
Elena Kistol
VGV.A. Gnetetskaya
V.A. Gnetetskaya
ARA.G. Rumyantsev
A.G. Rumyantsev

19 June 2026 in Neuromuscular Diseases
Verified
Journal Article
Open access
PDF file
TGT. A. Gremyakova
T. A. Gremyakova
ГАГремякова Т. А.
Гремякова Т. А.
OGO. I. Gremyakova
O. I. Gremyakova
ГИГремякова О. И.
Гремякова О. И.
TMT. V. Morozova
T. V. Morozova
НСНикитин С. С.
Никитин С. С.
Background. The authors present the Russian experience of clinical use of a gene therapy drug in the treatment of progressive Duchenne muscular dystrophy through exon 53 skipping, using the only drug of this class registered in Russia, viltolarsen (Viltepso®), as an example. It is approved for the treatment of patients with amenable DMD gene deletions, however, real-world clinical efficacy across different age groups requires further clarification. Aim. To evaluate the efficacy of viltolarsen in real world clinical practice in the Russian Federation, depending on age at treatment initiation and functional status. Materials and methods. The study included 48 patients aged 1.83 to 17.58 years with deletion mutations correctable by exon 53 skipping (del 43–52, 45–52, 48–52, 49–52, 50–52, 52) treated with viltolarsen. Patients were stratified into 4 cohorts: 1) ambulatory patients who initiated therapy under 4 years of age (n = 4); 2) ambulatory patients who initiated therapy at 4–7 years of age (n = 20); 3) ambulatory patients who initiated therapy at ≥8 years of age (n = 19); 4) non-ambulatory patients at therapy initiation (n = 5). Standard functional tests, pulmonary function and cardiac function were assessed. Mean treatment duration was 2.1 ± 1.1 years. Results. Viltolarsen, depending on the age of therapy initiation, improves and/or stabilizes functional parameters in ambulatory children with Duchenne muscular dystrophy, and significantly prolongs the age of ability to walk independently: 18 out of 19 patients in cohort 3 at high risk of loss of ambulation (mean age 11.6 ± 1.6 years old) maintained the ability to walk, whereas control group patients lost this function at 8.9 ± 0.9 years old (p 0.01). Loss of ambulation in the studied cohort was associated with sharp deviations from typical child development: extreme obesity, growth spurts, cardiorespiratory problems. In patients who started therapy after loss of independent ambulation, no marked deterioration in mean cardiac function and respiratory function was observed during the follow-up period. No signs of clinically significant renal function deterioration during the follow-up period, as determined by cystatin C levels, were observed (0.896 ± 0.027 (n = 26) versus 0.941 ± 0.021 (n = 47), p 0.05). Conclusion. Preliminary study results have shown that viltolarsen improves and/or stabilizes functional outcomes in ambulatory children with DMD, significantly prolongs the age of independent ambulation, and stabilizes cardiorespiratory parameters in non-ambulatory patients. Early initiation of comprehensive multidisciplinary management of patients with Duchenne muscular dystrophy is required as a mandatory basis for pathogenetic therapy.

15 December 2023 in Pediatria. Journal named after G.N. Speransky
Verified
Journal Article
Closed access
TGT.A. Gremyakova
T.A. Gremyakova
IAI.V. Anisimova
I.V. Anisimova
SASvetlana Artemyeva
Svetlana Artemyeva
EBE.N. Baybarina
E.N. Baybarina
ABA.A. Baranov
A.A. Baranov
MRMoscow State Duma Of The Federal Assembly Of Russia
Moscow State Duma Of The Federal Assembly Of Russia
Вам открыли доступ к файлу. Отправлено с помощью Облако Mail.ru.